Federal Supply Schedule (FSS) Pricing Added to ProspectoRx From Elsevier / Gold Standard

TAMPA, Florida, March 3, 2011 /PRNewswire/ --

- Addition Creates a More Comprehensive Pricing and Analytics Tool for Pharmaceutical Companies, Pharmacy Benefits Managers and Pharmacy Headquarters

Elsevier / Gold Standard (http://www.goldstandard.com/index.html), a leading developer of drug databases and medication management solutions, announced today several enhancements to its pricing tool, ProspectoRx ( http://www.goldstandard.com/pages/ProspectoRx-AboutProspectoRx.html), including the addition of Federal Supply Schedule (FSS) pricing to facilitate pricing analysis.

The rate and frequency at which drug prices change in today's competitive environment make current, accurate and easily accessible pricing information critical to success in the pharmaceutical industry. The addition of FSS pricing for analysis makes ProspectoRx an even more comprehensive pricing and analytics tool by providing immediate access to competitive federal pricing, better marketplace knowledge and less time spent researching.

"As the only real-time pricing tool available, our customers rely on ProspectoRx for current and accurate information," stated Kay Morgan, SVP, Drug Products and Industry Standards for Elsevier / Gold Standard. "Our customers requested to make their analysis of markets and pricing faster and easier, so the addition of FSS will further aid them with the pricing analysis they need to make decisions and form the right strategies."

Derived from Elsevier / Gold Standard's Alchemy (http://www.goldstandard.com/pages/alchemy.html?epm=1_1) drug product and pricing files, ProspectoRx includes extensive information on brand and generic drugs, delivering immediate access to price changes and new product information. It already includes extensive pricing information, including: reported Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), Direct Price (DP), and Federal Upper Limit (CMS-FUL), as well as Calculated Average Wholesale Price (C-AWP) 1.20 and 1.25, and Calculated Federal Upper Limit (C-CMS-FUL).

Other enhancements include multiple watch lists and enhanced price change notifications, a new label name search box for market class, along with an improved interface, help tab, and report download capabilities.

For more information on how to stay current on drug prices, contact Elsevier / Gold Standard at goldstandard@elsevier.com or +1-866-417-9150.

About Elsevier / Gold Standard

Based in Tampa, FL, Elsevier / Gold Standard uses innovative technologies to provide a complete suite of drug information and decision support solutions. With a tenacious commitment to product quality, Elsevier / Gold Standard solutions empower healthcare organizations, professionals and consumers to meet the most pressing healthcare challenges, improve patient safety and ensure optimal outcomes. To learn more about Elsevier / Gold Standard, visit http://www.goldstandard.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com), SciVerse Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com ), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    
    Media Contact

    Tom Reller
    +1-212-462-1912
    T.Reller@Elsevier.com